Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by PATRICIA TRONCOSO and LOUIS L PISTERS.
PATRICIA TRONCOSO
Connection Strength
2.355
LOUIS L PISTERS
  1. The association of body mass index with tumor aggression among men undergoing radical prostatectomy. Urol Oncol. 2024 04; 42(4):116.e1-116.e7.
    View in: PubMed
    Score: 0.235
  2. A feasibility study of cryotherapy followed by radical prostatectomy for locally advanced prostate cancer. J Urol. 1999 Feb; 161(2):509-14.
    View in: PubMed
    Score: 0.166
  3. Salvage prostatectomy for post-radiation adenocarcinoma with treatment effect: Pathological and oncological outcomes. Can Urol Assoc J. 2017 Jul; 11(7):E277-E284.
    View in: PubMed
    Score: 0.149
  4. Tissue Effects in a Randomized Controlled Trial of Short-term Finasteride in Early Prostate Cancer. EBioMedicine. 2016 May; 7:85-93.
    View in: PubMed
    Score: 0.137
  5. Pathological characteristics of prostate cancer recurrence after radiation therapy: implications for focal salvage therapy. J Urol. 2012 Jul; 188(1):98-102.
    View in: PubMed
    Score: 0.104
  6. Are there differences in zonal distribution and tumor volume of prostate cancer in patients with a positive family history? Int Braz J Urol. 2010 Sep-Oct; 36(5):571-82.
    View in: PubMed
    Score: 0.093
  7. Morphologic characterization of preoperatively treated prostate cancer: toward a post-therapy histologic classification. Eur Urol. 2010 Jun; 57(6):1030-8.
    View in: PubMed
    Score: 0.087
  8. Cancer ablation with regional templates applied to prostatectomy specimens from men who were eligible for focal therapy. BJU Int. 2009 Aug; 104(4):490-7.
    View in: PubMed
    Score: 0.083
  9. Prostate cancer invading the rectum: a clinicopathological study of 18 cases. Pathology. 2009; 41(6):539-43.
    View in: PubMed
    Score: 0.083
  10. Can digital rectal examination or transrectal ultrasonography biopsy findings predict the side of nodal metastasis in prostate cancer? Urol Oncol. 2008 Jan-Feb; 26(1):25-30.
    View in: PubMed
    Score: 0.076
  11. Surgically managed lymph node-positive prostate cancer: does delaying hormonal therapy worsen the outcome? BJU Int. 2007 Feb; 99(2):321-5.
    View in: PubMed
    Score: 0.071
  12. Biochemical disease-free survival in men younger than 60 years with prostate cancer treated with radical prostatectomy. Urology. 2006 Apr; 67(4):769-73.
    View in: PubMed
    Score: 0.068
  13. Validation of a prognostic blood-based sphingolipid panel for men with localized prostate cancer followed on active surveillance. Biomark Res. 2024 Nov 09; 12(1):134.
    View in: PubMed
    Score: 0.062
  14. A phase II trial of apalutamide for intermediate-risk prostate cancer and molecular correlates. BJU Int. 2024 Sep; 134(3):449-458.
    View in: PubMed
    Score: 0.060
  15. Integrative Molecular Analyses of the MD Anderson Prostate Cancer Patient-derived Xenograft (MDA PCa PDX) Series. Clin Cancer Res. 2024 May 15; 30(10):2272-2285.
    View in: PubMed
    Score: 0.060
  16. Evidence that transfer of functional p53 protein results in increased apoptosis in prostate cancer. Clin Cancer Res. 2004 Apr 15; 10(8):2587-93.
    View in: PubMed
    Score: 0.060
  17. Ductal Prostate Cancers Demonstrate Poor Outcomes with Conventional Therapies. Eur Urol. 2021 02; 79(2):298-306.
    View in: PubMed
    Score: 0.047
  18. The MD Anderson Prostate Cancer Patient-derived Xenograft Series (MDA PCa PDX) Captures the Molecular Landscape of Prostate Cancer and Facilitates Marker-driven Therapy Development. Clin Cancer Res. 2020 09 15; 26(18):4933-4946.
    View in: PubMed
    Score: 0.046
  19. Patterns of metastases of prostatic ductal adenocarcinoma. Cancer. 2020 08 15; 126(16):3667-3673.
    View in: PubMed
    Score: 0.046
  20. Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancer. Sci Transl Med. 2020 04 01; 12(537).
    View in: PubMed
    Score: 0.045
  21. Determining Clinically Based Factors Associated With Reclassification in the Pre-MRI Era using a Large Prospective Active Surveillance Cohort. Urology. 2020 04; 138:91-97.
    View in: PubMed
    Score: 0.044
  22. Intraprostatic AD-p53 gene therapy followed by radical prostatectomy: feasibility and preliminary results. Prostate Cancer Prostatic Dis. 1999 Nov; 2(S3):S27.
    View in: PubMed
    Score: 0.044
  23. Clinical and Biological Characterisation of Localised High-risk Prostate Cancer: Results of a Randomised Preoperative Study of a Luteinising Hormone-releasing Hormone Agonist with or Without Abiraterone Acetate plus Prednisone. Eur Urol. 2019 10; 76(4):418-424.
    View in: PubMed
    Score: 0.043
  24. Prolonged survival with metastatic prostate cancer to bone. J Urol. 1998 Jun; 159(6):2100.
    View in: PubMed
    Score: 0.040
  25. Baseline and longitudinal plasma caveolin-1 level as a biomarker in active surveillance for early-stage prostate cancer. BJU Int. 2018 01; 121(1):69-76.
    View in: PubMed
    Score: 0.038
  26. Homozygous deletions at 8p22 and 8p21 in prostate cancer implicate these regions as the sites for candidate tumor suppressor genes. Oncogene. 1995 Nov 16; 11(10):2121-6.
    View in: PubMed
    Score: 0.033
  27. Disease reclassification risk with stringent criteria and frequent monitoring in men with favourable-risk prostate cancer undergoing active surveillance. BJU Int. 2016 07; 118(1):68-76.
    View in: PubMed
    Score: 0.032
  28. c-met proto-oncogene expression in benign and malignant human prostate tissues. J Urol. 1995 Jul; 154(1):293-8.
    View in: PubMed
    Score: 0.032
  29. Integrating chemohormonal therapy and surgery in known or suspected lymph node metastatic prostate cancer. Prostate Cancer Prostatic Dis. 2015 Sep; 18(3):276-80.
    View in: PubMed
    Score: 0.032
  30. Integrated Hedgehog signaling is induced following castration in human and murine prostate cancers. Prostate. 2013 Jan; 73(2):153-61.
    View in: PubMed
    Score: 0.026
  31. Persistent, biologically meaningful prostate cancer after 1 year of androgen ablation and docetaxel treatment. J Clin Oncol. 2011 Jun 20; 29(18):2574-81.
    View in: PubMed
    Score: 0.024
  32. Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 04; 101(5):306-20.
    View in: PubMed
    Score: 0.021
  33. Randomized phase II trial evaluation of erectile function after attempted unilateral cavernous nerve-sparing retropubic radical prostatectomy with versus without unilateral sural nerve grafting for clinically localized prostate cancer. Eur Urol. 2009 May; 55(5):1135-43.
    View in: PubMed
    Score: 0.020
  34. A randomized prospective trial evaluating testosterone, haemoglobin kinetics and quality of life, during and after 12 months of androgen deprivation after prostatectomy: results from the Postoperative Adjuvant Androgen Deprivation trial. BJU Int. 2007 Jul; 100(1):63-9.
    View in: PubMed
    Score: 0.019
  35. Initial modulation of the tumor microenvironment accounts for thalidomide activity in prostate cancer. Clin Cancer Res. 2007 Feb 15; 13(4):1224-31.
    View in: PubMed
    Score: 0.018
  36. Changes in serum proteomic patterns by presurgical alpha-tocopherol and L-selenomethionine supplementation in prostate cancer. Cancer Epidemiol Biomarkers Prev. 2005 Jul; 14(7):1697-702.
    View in: PubMed
    Score: 0.016
  37. Prostate carcinoma with testicular or penile metastases. Clinical, pathologic, and immunohistochemical features. Cancer. 2002 May 15; 94(10):2610-7.
    View in: PubMed
    Score: 0.013
  38. The association of p21((WAF-1/CIP1)) with progression to androgen-independent prostate cancer. Clin Cancer Res. 2002 Mar; 8(3):775-81.
    View in: PubMed
    Score: 0.013
  39. Neoadjuvant chemotherapy and hormonal therapy followed by radical prostatectomy: feasibility and preliminary results. J Clin Oncol. 2000 Mar; 18(5):1050-7.
    View in: PubMed
    Score: 0.011
  40. p53 mutations in prostate cancer bone metastases suggest that selected p53 mutants in the primary site define foci with metastatic potential. J Urol. 1999 Jan; 161(1):304-8.
    View in: PubMed
    Score: 0.010
  41. Expression of bcl-2 oncoprotein and p53 protein accumulation in bone marrow metastases of androgen independent prostate cancer. J Urol. 1997 Feb; 157(2):569-74.
    View in: PubMed
    Score: 0.009
  42. Consistent expression of an epithelial cell adhesion molecule (C-CAM) during human prostate development and loss of expression in prostate cancer: implication as a tumor suppressor. Cancer Res. 1995 Mar 15; 55(6):1215-20.
    View in: PubMed
    Score: 0.008
  43. Genetic instability in microsatellite sequences in prostate-cancer. Int J Oncol. 1994 Oct; 5(4):921-4.
    View in: PubMed
    Score: 0.008
  44. Trisomy 7: a potential cytogenetic marker of human prostate cancer progression. Genes Chromosomes Cancer. 1994 Jan; 9(1):19-27.
    View in: PubMed
    Score: 0.007
  45. Biomarkers associated with prostate cancer progression. J Cell Biochem Suppl. 1994; 19:208-16.
    View in: PubMed
    Score: 0.007
  46. p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J Natl Cancer Inst. 1993 Oct 20; 85(20):1657-69.
    View in: PubMed
    Score: 0.007
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.